Background: Aryl hydrocarbon receptor (AHR), commonly known as an environmental sensor involved in the metabolism and elimination of xenobiotic substances, is also an important modulator in the development and functioning of the immune system. AHR expression is varied in the T cell subsets with the highest expression in T-helper 17 and T regulatory cells. It has been reported that AHR can act as a tumor promoter or a tumor suppressor, depending on the tumor type. Methods: In an effort to understand the role played by AHR in tumor growth, the MC38 syngeneic colon carcinoma tumor model was used on C57BL/6 or ahr knockout (KO, -/-) mice with or without AHR antagonist (CH223191) treatment. Tumor sizes were measured, and biomarkers were quantified in tumor microenvironment and draining lymph nodes using flow cytometry. Enzyme-linked immunosorbent assay was used to determine the amount of cytokines in tumors. Results: In ahr deficient mice, MC38 tumors progress more rapidly than in wild-type mice, accompanied by an increase in tumor-associated macrophages and M2 macrophages and a decrease in CD8a positive cytotoxic lymphocytes. Analysis of cytokines in the tumor microenvironment reveals a pro-inflammatory phenotype. Similar changes were observed by pharmacologic blockade of the receptor using CH223191. Conclusion: AHR acts as a tumor suppressor in mice implanted with MC38 colon carcinoma cells as evidenced by either a blockade or deficiency of AHR.
Introduction
Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor which resides in the cytoplasm in its latent state. 1 Mouse AHR, which was cloned in the innate and adaptive immune system, AHR is expressed in dendritic cells (DCs), 8 macrophages, 9 natural killer (NK) cells, 10 and intraepithelial lymphocytes. 11 Among T cells, AHR is silent in naïve, Th1, and Th2 cells, but its expression is high in Th17, Tr1, and Treg cells. 12, 13 It has been shown that AHR affects Treg and Th17 cell differentiation in a liganddependent manner -treatment with TCDD in mice increased Treg cells and ameliorated autoimmune disease EAE while treatment with 6-formylindolo [3,2-b] carbazole led to increased Th17 cells and exacerbated EAE. 14 Treatment with 2-(1H-indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester, an endogenous AHR ligand, promoted tolerogenic DCs, resulting in increased Foxp3+ Treg cells and reduced EAE symptoms. 15 In addition, AHR can either be a tumor promoter or suppressor depending on the tumor type. Its role in epithelial-mesenchymal transition and progression is also controversial. Differential AHR expression has been observed in tumor versus normal tissues; it can be considered either a negative or a positive prognostic factor. 16 The reason for the dual role of AHR in cancer is not known. Many AHR agonists such as TCDD are known carcinogens. 17 Kynurenine, an AHR endogenous ligand generated through the indoleamine 2,3-dioxygenase (IDO)-mediated tryptophan metabolism, is associated with cancer progression by increasing Treg cells and suppressing T effector cells. 18 Some AHR activators such as β-naphthoflavone, indole-3-carbinol (I3C, from cruciferous vegetables), and its dimer 3,3ʹ-diindolylmethane exhibit promising anti-tumor activities. 16 There is evidence that AHR may curb tumor growth: for example, AHR appears to lower the risk of liver carcinogenesis, 19 colon cancer, 20 and ovarian cancer. 21 In lung cancer, an increase in AHR expression decreases autophagy which leads to tumor suppression; in addition, it inhibits migration of lung cancer cell lines. 22 On the contrary, AHR agonists drive the growth of gliomas 23 and breast cancer. 24 Based on the conflicting role of AHR in cancer, we wanted to better understand its role in tumor growth using a syngeneic mouse colon carcinoma model. MC38 is a syngeneic mouse colon adenocarcinoma tumor model on C57BL/6 background. Here we provide evidence supporting that AHR can act as a tumor suppressor. Changes in tumor burden after activation of the receptor using TCDD, blockade of the receptor using the antagonist CH223191, and removal of the receptor function using ahr deficient mice were examined. The tumor microenvironment was interrogated by examining the tumor-infiltrating leukocytes (TILs) along with cytokine and chemokine profiling in an effort to understand changes in tumor burden. Analysis of cytokines in the tumor microenvironment was performed to determine the inflammatory status.
Material and methods Animals
For all tumor burden studies, the wild-type (WT) C57BL/6 mice were purchased from Jackson Laboratories. The mice were housed in the Bristol-Myers Squibb animal facility per the company's guidelines. All animal studies were approved by the Institutional Animal Care and Use Committee of the company. The animal facility at Bristol Myers Squibb in Redwood City, California, is an AAALAC accredited facility. The mice used in the study were all female and 8 weeks of age at the time of tumor implants. For the studies involving ahr WT and knockout (KO, -/-) mice, these mice were obtained from matings of male and female ahr heterozygous (+/-) littermates that were purchased from Jackson Laboratories. The ahr deficient mice were originally generated by the Bradfield's group. 25 Some of WT and KO mice were also obtained from ahr (-/-) X ahr (-/-) and ahr (+/+) X ahr (+/+) matings, respectively. The KO mice from both sets of matings did not exhibit any differences in their tumor burden. These mice were housed and bred at the BristolMyers Squibb animal facility. Female mice between 8 and 12 weeks of age at the time of tumor implants were used in the study. All WT and KO mice that were put on a tumor study had an acclimatization period of 5 days in the protocol room.
Genotyping
Genotyping was done by polymerase chain reaction (PCR) to distinguish between WT and KO mice. DNA was extracted using Extract N Amp Tissue extraction kit. PCR was set up using 1X PCR buffer from Sigma using the primers 5ʹ-GGATTTGACTTAATTCCTTCAGCGG-3ʹ (wild type reverse), 5ʹ-TCTTGGGCTCGATCTTGTGT CAGGAACAGG-3ʹ (common) and 5ʹ-TGGATGTGGAA TGTGTGCGAG-3ʹ (mutant reverse). The PCR sequences were obtained from Jackson Laboratory genotyping database/repository. Tumor model 8-to 12-week-old C57BL/6 or ahr KO (-/-) mice were injected subcutaneously on the right flank with either 2×10 6 MC38 cells or 1×10 6 B16F10 cells. TCDD dissolved in DMSO (at 50 µg/mL concentration) was purchased from Cambridge Isotope Laboratories. TCDD was mixed with NF grade corn oil (CO136-25ML, Spectrum Chemicals) and was administered intraperitoneally at 1 µg per mouse, one day prior to MC38 cell implant to ensure that AHR was activated before implantation. CH223191 (C8124-5MG) and DMSO were purchased from Sigma-Aldrich, mixed in corn oil and administered at 10 mg/kg body weight orally, once a day starting on day 7. On day 7, the mice were randomized based on the tumor burden and divided into the control and the treatment group such that both groups had the same average tumor burden. The weight and tumor burden were measured twice a week using Studylog database (from Studylog Systems Inc.). The height, width, and length of the tumors were measured using a caliper, and the tumor burden was calculated using the formula LxWxH/2. The tumor study involving ahr WT and KO mice did not receive any treatment. The health of the mice and husbandry was monitored on a daily basis per the guidelines of Bristol-Myers Squibb animal facility. For the immunophenotyping experiment, the tumors and tumor-draining lymph nodes constituting the axillary, brachial, and inguinal lymph nodes on the tumor-bearing side were excised on day 17 for TIL analysis by flow cytometry. Cytokine/chemokine analysis of the tumor microenvironment
Flow cytometry
The tumors from ahr WT, ahr KO, and vehicle-and CH223191-treated mice were harvested and ground in RPMI medium using gentleMACS TM tissue grinder. The samples were filtered using a 100 µM filter and spun at 400 g for 5 mins at 4°C; the supernatant was used for analysis. The cytokine and chemokine analysis was done using Millipore's bead-based Luminex assays and run on Magpix. TGF-β enzyme-linked immunosorbent assay (ELISA) was done using ELISA kit from R n D Systems.
RT-PCR
RNA from MC38 and Hepa1c1c7 cells was extracted using Direct-zol Total RNA extraction kit (Zymo Research). RNA quantitation was done using a QIAxpert (Qiagen). 1 µg of RNA per reaction was used to set up the cDNA reaction. cDNA was prepared immediately from RNA using the SuperScript III first strand synthesis super mix for qRT-PCR (Thermo Fisher Scientific) following manufacturer's instructions. The prepared cDNA was immediately used to set up the RT-PCR reaction. 2 µl of cDNA was used per sample to set the RT-PCR reaction with three technical replicates. Real-time PCR was done using Sso advanced SYBR green master mix (Bio-Rad). The samples were run on the LC480 cycler (Roche). The housekeeping gene gapdh was used as the standard. Fold induction was calculated using the 2 −ΔΔC T method. 26 All the primers for the assay were ordered from Integrated DNA Technologies. The primer sequences are shown in Table 1 .
Statistical analysis
Statistics were performed using GraphPad PRISM 7. Error bars represent standard deviation. For differences in tumor burden between groups, one-way and two-way ANOVA (with Bonferroni post test) were used. Differences between ahr WT versus KO mice and vehicle versus CH223191-treated mice among different lymphocyte subsets were determined by the Student's t-test (unpaired) comparing the means of the two study groups. A p-value of <0.05 was considered as a significant difference.
Results

MC38 tumor growth was promoted in ahr deficient mice
We examined whether AHR would have any role in MC38 tumor growth. MC38 tumor experiments using ahr deficient (KO) and wild-type (WT) C57BL/6 mice were performed as described ( Figure 1A ). Each group consisted of 8-10 mice. On day 7, mice were not randomized, but the average tumor burdens in the WT and KO mice were similar. The tumors between the two groups started showing differences on day 17 post-implantation and became significant by day 21 ( Figure 1B ). The tumor burden in the ahr KO mice was almost double the volume to their WT counterparts on day 21.
AHR antagonist promoted MC38 tumor growth
Next, we examined whether inhibition of AHR function would elicit similar tumor burden as observed in the ahr deficient mice. CH223191, a highly specific AHR antagonist, 27 was administered at a daily dose of 10 mg/kg, starting day 7 until the end of the tumor study ( Figure 1C ). Mice in the study were in good health, and the administration of the compound did not appear to cause any adverse effects. Mice that developed tumor ulcerations were removed from the study; more specifically, tumors on three mice (out of 10) were found ulcerated on day 17 and were removed from the experiment. We began to observe significant changes in the tumor burden starting on day 17 ( Figure 1D ). The study was terminated at day 21 as most of the mice in the study had reached the maximum tumor volume of 2,000 mm 3 or exhibited ulcerated tumors. We observed that the MC38 tumor burden was increased when AHR was inhibited by an AHR-specific antagonist.
B16F10 tumor grew faster in ahr deficient mice
Next, we examined whether AHR would suppress another type of tumor growth in C57BL/6 mice. One million B16F10 melanoma cells were implanted in co-housed ahr WT (+/+) and ahr KO (AHR-/-) mice and remained untreated for the duration of the experiment. Same protocol as described in Figure 1A was followed. The tumor measurements started on day 7 with a starting number of 10-11 mice per group. There were significant changes in the tumor burden on day 16 post implantations. Similar to MC38 tumors, B16F10 tumors grew faster in the absence of AHR in comparison to the wild-type counterparts ( Figure 1E ). Unlike the MC38 tumor burden study, this study could not be continued beyond day 16 as mice developed ulcerated tumors and their health status, monitored by weight and health, began to decline.
B16F10 tumor did not exhibit differences in the tumor burden with or without CH223191 treatment
Next, we examined whether inhibition of AHR function would increase the B16F10 tumor growth. A B16F10 tumor study was done as described in Figure 1C , except that 1 million B16F10 cells were subcutaneously implanted. On day 7, the tumors were measured, the mice randomized based on tumor burden, then divided into the treatment and control groups. The antagonist CH223191 or vehicle was administered every day orally starting from day 7 and continued until the end of the tumor study. There were no significant changes in the tumor burden up to day 16 after the subcutaneous implants ( Figure 1F ). The study had to be brought down because many mice developed ulcerated tumors, and their health began to decline.
Multiple dosing of TCDD was required to suppress MC38 tumor growth
Next, we examined whether activation of AHR function by an exogenous ligand would suppress the MC38 tumor growth. We performed tumor burden experiment with a single dose of TCDD ( Figure 2A ) and observed that there was no significant change in the tumor burden when mice were treated with 1 µg of TCDD ( Figure 2B ). However, when mice were treated with three 1 µg doses of TCDD (day 1, 7, and 10), the tumor growth was significantly suppressed on day 21 and 24 ( Figure 2C ). There were no gross changes in body weight or the health status of the mice with multiple doses of TCDD. responsive Hepa1c1c7 mouse hepatoma cells were used as the control for comparison. Expression levels of cyp1a1 in Hepa1c1c7 in comparison to that of MC38 were measured at 6 and 24 hrs in the presence or absence of 1nM TCDD. The induced expression levels of cyp1a1 in Hepa1c1c7 was much higher than that of MC38 cells -78-fold versus 1.2-fold after 24 hrs ( Figure 3A) . To determine the consequences of TCDD incubation of MC38 and B16F10 cells, these cells were exposed to 1nM TCDD and the expression of cyp1a1 was measured at 3, 6, 18, and 24 hrs after TCDD treatment. There was very modest induction of the cyp1a1 message in MC38 cells; it was highest 3 hrs after TCDD treatment (2.7-fold) and decreased thereafter to 24 hrs ( Figure 3B ). Contrarily, the cyp1a1 message levels of B16F10 were quite steady over the 24-hr period and were significantly higher than that of MC38 (17-to 19-fold) ( Figure 3C ). Moreover, in MC38 cells treated with 1nM TCDD, there was no detectable induction among six AHR target genes -ugt1a1, ahrr, nqo, cyp1a1, cyp1a2, and cyp1b1 ( Figure 3D ), suggesting that AHR may not elicit normal function in MC38 cells. Perhaps AHR expression in MC38 cells may be irrelevant; thus, any effects on tumor burden should be mediated by the host AHR.
MC38 cells did not appear to possess appreciative AHR function
A decrease of the CD8/Treg ratio and NK cells and an increase of tumor-associated macrophages (TAMs) and M2 macrophages were observed in the tumor microenvironment of ahr deficient mice and CH223191-treated wild-type mice
Immune monitoring of TILs was undertaken to identify changes that correlated with differences in tumor burdens in either ahr deficient or wild-type mice treated with antagonist CH223191. Tumor burden differences were manifested at day 17 -same day when tumors were harvested for analysis. Fluorescence-activated cell sorting (FACS) analysis of TILs in WT versus ahr KO mice ( Figure 4 ) and WT mice ±CH223191 treatment ( Figure 5 ) revealed that an increase in MC38 tumor burden resulted in a small, but not significant, increase in Foxp3+ Treg cells in the tumor microenvironment ( Figures 4A and 5A ). However, there was a significant decrease in the CD8a+ T cells with increased tumor burden ( Figures 4B and 5B ). These changes became more apparent when we observed a clear, significant decrease in the CD8a to A Tumor/body wt. measured on D7, D10, D14, D17, D0: mc38 s.c. Expression of cytokines and chemokines in the tumor microenvironment of the ahr deficient and CH223191-treated wild-type mice revealed a pro-inflammatory status
Next, we examined the inflammation status of the tumor microenvironment by measuring the amount of various cytokines and chemokines. Eotaxin levels, a chemokine secreted by Th2 and other cell types in response to IL-4 and IL-13 to mobilize eosinophils from bone marrow to blood circulation, were significantly lower in tumor supernatants from ahr KO mice compared to WT mice ( Figure 6B ), although there was no difference in tumors of mice treated with vehicle and antagonist ( Figure 7A) . Notably, the levels of IFN-γ were significantly reduced with an increase in tumor burden ( Figures 6C and 7B ). There was no change in the levels of IL-1a, IL-2, IL-13, IL-10, MIG (CXCL9), and VEGF; however, there was a significant increase in the pro-inflammatory Table 2 ). CCL5/RANTES levels were also reduced as the tumor burden increased.
Discussion
We have used a mouse colon carcinoma syngeneic model to elucidate the role of AHR in cancer. Syngeneic models have an intact immune system and are very useful in understanding the role of immune system in modulating cancer growth. 28 Some of the commonly used syngeneic tumor models in cancer research are CT26 and MC38 colon carcinoma, B16F10 melanoma, and 4T1 breast cancer models. Preclinical data using surrogate antibodies supported clinical investigation, yielding to ultimate approval of human-specific PD-1 and CTLA-4 antibodies. In our studies, we have used MC38 and B16F10 syngeneic models to explore the AHR role in MC38 and B16F10 tumor progression. and Figure S1 ), suggesting that AHR is already active that further activation by a single dose of TCDD does not elicit any more AHR function. However, multiple doses of TCDD did suppress the MC38 tumor growth, validating that activation of the AHR function can curb tumor growth. Our B16F10 tumor study data showed increased tumor burden in ahr deficient mice, similar finding as reported by Sunwoo et al, 10 although no changes were seen when the receptor was blocked by CH223191. We observed that B16F10 tumors were much more aggressive and less consistent than the MC38 tumors, making it difficult to discern the AHR effect on tumor growth. In addition, we cannot rule out the possibility that our treatment of CH223191 was insufficient to block the overall AHR function since the B16F10 tumors possessed substantially higher AHR function, as compared to the MC38 tumors. Although both Sunwoo's and our groups observed increased tumor growth in ahr deficient mice when compared to the wild-type control, function of AHR in the stroma cells has been shown to drive the tumor growth. 29 Since these researchers used AHR-knockdown B16F10 cells for tumor study, it could be the off-target effect of the manipulated B16F10 cells that may contribute to tumor growth. Interestingly, our finding appears to contradict with a recent report stating that AHR can drive PD-1 expression in CD8+ T lymphocytes and in turn can promote mouse melanoma tumor growth. 30 Our observation Figure 6 Amount of cytokines and chemokines (A-M) in tumor microenvironment of wild-type (WT) vs ahr knockout (KO) C57BL/6 mice. Eotaxin, IFNγ, RANTES, IL-1b, IL-10, and TNF-α were reduced whereas IL-6 was increased in KO mice when compared to WT. Statistical analysis was done using unpaired Student's t-test. Error bars represent means±SD, n=8-10; *p<0.05; **p<0.005; ****p<0.0001.
that recruitment of CD8+ T cells into the tumor microenvironment was significantly reduced in mice with compromised AHR function may nullify the AHR-mediated PD-1 effect in these cells. It is interesting that we observed tumor promotion with AHR antagonism whereas some researchers observed otherwise, although differences in experimental design and environment are known to influence the outcome of a tumor study. Unlike the highly tumorigenic tumor-repopulating cells, IDO expression in MC38 cells was detected only after IFNγ treatment (data not shown). Realizing that the IFNγ levels were repressed in the MC38 tumor microenvironment in ahr deficient and , and TNF-α were reduced whereas IL-6 was increased with CH223191 treatment when compared to DMSO treatment. Statistical analysis was done using unpaired Student's t-test. Error bars represent means±SD, n=8-10; *p<0.05; **p<0.005; ***p<0.0005.
CH223191-treated mice, we argue that synthesis of kynurenine by MC38 tumors should be modest, if any, to affect the tumor burden. MC38 cells showed very low TCDD-dependent cyp1a1 expression when compared to Hepa1c1c7 cells, suggesting that the receptor, which is detectable by Western analysis (data not shown), might not be active. Thus, the AHRmediated increase in tumor burden is most likely mediated by stromal cells and TILs rather than MC38 cells. We performed a comprehensive FACS analysis of TILs composed of NK cells, T cell subsets, and myeloid cells in search of evidence which could explain our tumor burden studies. There was a reduction in total NK cell numbers and activated NK cells with increased tumor burden. It has been demonstrated that AHR is essential for the cytolytic activity of NK cells in RMA-S cells implanted in ahr deficient mice. 10 Unlike RMA-S cells, however, MC38 cells express MHC class I which may negatively affect NK cell function; whether NK cells play a role in controlling MC38 cells is remained to be determined. Analysis of the myeloid populations demonstrated that there were no changes in the tumor-infiltrating Ly6C+ monocytes or neutrophils. Among DCs, which are the primary antigen presenting cells, 31 no changes were observed in the infiltrating DCs, the classical DCs (CD11b), cross-presenting DCs (CD103), and activated DCs (CD80 and CD86, data not shown) with increased tumor burden. However, a significant reduction in F4/80+ TAMs and CD206+ macrophages was observed in the wild-type mice. TAMs are frequently detected in the tumor microenvironment.
32
They are differentiated myeloid populations with immune suppressive properties that are thought to block anti-tumor immunity and promote angiogenesis. 33 The CD206+ macrophages or M2 macrophages are also thought to be immune suppressive and promote tumor growth. 34 It appeared that inhibition of TAM and M2 macrophages into the tumor microenvironment is partly responsible for the AHR function in suppressing tumor growth. Flow cytometry analysis of tumor lymphocytes revealed a significant decrease in cytotoxic T lymphocytes (CD8a+) and CD8/Treg ratio in ahr deficient and antagonist-treated mice when compared to controls. This is in line with our finding that AHR suppresses the MC38 tumor growth by causing more cytotoxic T cell recruitment into the tumor microenvironment. Paradoxically, it has been reported that activation of AHR by kynurenine would trigger precisely the opposite effect on Treg and CD8a+ T cells. 18 It is conceivable that different endogenous ligands are at play in this MC38 tumor microenvironment. 14 There were no changes in Ki67 staining in Foxp3+ Treg and CD8a+ T cells in the ahr deficient and antagonist-treated mice when compared to the wildtype counterparts (data not shown), suggesting that the reduced cytotoxic T lymphocytes was due to reduced infiltration of these cells into the tumor environment but not reduced proliferation. Intratumoral cytokine analysis of the tumor microenvironment revealed an increase in the pro-inflammatory cytokine IL-6 and the reduction of IFN-γ, TNF-α, and IL-1b with increased tumor burden in the ahr deficient and antagonisttreated wild-type mice when compared to controls. There was a reduction in the amount of IL-10, an anti-inflammatory cytokine, in the ahr deficient and antagonist-treated mice. IL-12 is a cytokine that is involved in the differentiation of Th1 cells, mainly secreted by DCs, which activates effector T and NK cells and is involved in IFN-γ production and activation of anti-tumor immunity. 34 The IL-12p40 and p70 subunits of IL-12 cytokine were reduced in both the antagonist treated group and in the KO mice, consistent with the weaker anti-tumor T cell response. Likewise, reductions in RANTES/CCL5, a chemoattractant for T cells, basophils, and other leucocytes, 35 maybe consistent with lower levels of CD8a T cell infiltration into tumors from antagonist-treated or KO mice. Based on the cytokine/chemokine analysis of the tumor milieu, there is a shift towards a pro-inflammatory environment by AHR and a chronic pro-inflammatory tumor environment is thought to result in tumor initiation and/or progression.
Conclusion
Collectively, we conclude that AHR plays a crucial role in the MC38 tumor development in C57BL/6 mice, the absence of which leads to tumor progression by reducing the infiltration of anti-tumor cytotoxic T lymphocytes, promoting the recruitment of F4/80+ TAMs and CD206+ M2 macrophages, and promoting a proinflammatory tumor microenvironment.
Supplementary materials
Effect of TCDD on LPS-elicited humoral challenge LPS (Lipopolysaccharide) is a component of the bacterial cell wall and an endotoxin which elicits an innate immune response via TLR4 pathway and also a humoral immune response mediated by CD4+ T cells. This experiment was based on the paper from Kaminski et al. 1 The idea behind using this model was to see if the TCDD dosage of 1 µg per mouse suppresses the activation of humoral response initiated by 25 µg of LPS.
The experiment was done as described in Figure S1 . Mouse splenocytes were plated into a 96-well ELISPOT assay plate, and the frequency of the IgM-producing plasma cells was measured. There was an increase in the number of IgM-producing plasma cells upon LPS challenge. This response was reduced by almost three-fold in mice that were exposed to TCDD prior to LPS challenge. In the DMSO+LPS group that received no TCDD, the humoral response was similar to the LPS alone group. The untreated group did not elicit any humoral response.
Next, CD138+ plasma cells were enumerated by FACS. Plasma cells are terminally differentiated B cells that produce specific antibodies for the antigen they have encountered. CD138 (Syndecan-1) is a specific plasma cell surface marker which B cells acquire after antigendriven differentiation. CD19 was also used as a B-lymphocyte marker. In supplementary Figure S1C , LPS challenge in the LPS and DMSO+LPS groups resulted in increased numbers of CD138 hi plasma cells. In supplementary Figure S1D , plasma cell populations identified as CD19 hi CD138 hi cells were measured and a 3-fold reduction was observed in the TCDD-treated group. Therefore, TCDD at 1 µg/ mouse suppressed the humoral response elicited by LPS challenge as measured by CD19 hi CD138 hi cells.
With the FACS analysis of B cells from the LPS challenge and the T cell subsets (from spleen and tumor), 1 µg/mouse TCDD dose is sufficient to suppress an LPS-elicited humoral response, the effector CD4+ T cells in the spleen and the CD8+ T cells in the tumor. However, this dosage has no effect on tumor volume. Therefore, it was decided to increase the TCDD dosing frequency, but below the lethal dose of TCDD (LD 50 ), namely 160 µg/kg for C57BL/6.
